HCG (Human Chorionic Gonadotropin): The LH Analog in Reproductive Medicine

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is HCG?

Human chorionic gonadotropin (HCG) is a heterodimeric glycoprotein hormone composed of an alpha subunit (common to LH, FSH, and TSH) and a unique beta subunit that confers biological specificity. It is naturally produced by syncytiotrophoblast cells of the placenta during pregnancy and is the hormone detected by standard pregnancy tests. HCG is the most abundant hormone produced during human pregnancy, with levels peaking at approximately 100,000 mIU/mL during the first trimester.

The critical feature that makes HCG clinically valuable beyond pregnancy is its structural and functional homology with luteinizing hormone (LH). Both hormones bind to the same receptor — the LH/CG receptor (LHCGR) — but HCG has a significantly longer half-life (24–36 hours vs. 20 minutes for LH), making it more practical for clinical use. For context on hormonal peptides in reproductive health, see our guide to hormonal and reproductive peptides.

Property	Detail
Full Name	Human Chorionic Gonadotropin
Structure	Heterodimeric glycoprotein (alpha + beta subunit)
Molecular Weight	~36,700 Da
Receptor	LH/CG receptor (LHCGR)
Half-Life	24–36 hours
Natural Source	Placental syncytiotrophoblast
Pharmaceutical Sources	Urinary-derived (Pregnyl, Novarel) and recombinant (Ovidrel)
FDA Status	Approved for cryptorchidism, hypogonadism, ovulation induction

Mechanism of Action

HCG functions as an LH analog, binding to and activating the LH/CG receptor expressed on target tissues in both males and females. This receptor is a G-protein-coupled receptor that signals primarily through the Gs-cAMP-protein kinase A pathway, though additional signaling cascades including ERK/MAPK and PI3K/AKT are also engaged.

In Males

• Leydig cell stimulation: HCG binds LHCGR on Leydig cells in the testes, stimulating the conversion of cholesterol to pregnenolone (the rate-limiting step) and subsequent testosterone synthesis via the steroidogenic pathway.
• Intratesticular testosterone: The testosterone produced within the testes achieves concentrations 50–100 times higher than serum levels, which is critical for supporting Sertoli cell function and spermatogenesis.
• Spermatogenesis support: By maintaining intratesticular testosterone, HCG indirectly supports the entire process of sperm production, from spermatogonial stem cell differentiation through mature sperm formation.

In Females

• Ovulation trigger: HCG mimics the natural LH surge, triggering final oocyte maturation, cumulus expansion, and follicular rupture (ovulation) approximately 36–40 hours after administration.
• Corpus luteum support: HCG maintains the corpus luteum during early pregnancy, sustaining progesterone production until the placenta assumes this function at approximately 8–10 weeks of gestation.
• Theca cell stimulation: HCG stimulates androgen production in theca cells, providing substrate for aromatase in granulosa cells to produce estradiol.

Research and Clinical Applications

Male Hypogonadotropic Hypogonadism

HCG has been a cornerstone of treatment for male hypogonadotropic hypogonadism for decades. In men with insufficient LH secretion due to pituitary or hypothalamic dysfunction, HCG restores Leydig cell stimulation and testosterone production. Standard protocols typically involve 1,500–4,000 IU administered 2–3 times per week, titrated to achieve target testosterone levels.

Adjunct to Testosterone Replacement Therapy

Perhaps the most discussed modern application of HCG is its use alongside exogenous testosterone to preserve testicular function. When men receive exogenous testosterone, the HPG axis negative feedback suppresses LH secretion, leading to reduced intratesticular testosterone, impaired spermatogenesis, and testicular atrophy. Co-administration of HCG (typically 500–1,000 IU 2–3 times weekly) replaces the LH signal and can maintain testicular volume and, in many cases, spermatogenesis.

Assisted Reproduction

HCG remains the most widely used ovulation trigger in IVF and other assisted reproduction protocols. A single injection of 5,000–10,000 IU of urinary HCG or 250 mcg of recombinant HCG is administered when lead follicles reach appropriate size, triggering final oocyte maturation 34–36 hours before egg retrieval. The primary risk of this approach is ovarian hyperstimulation syndrome (OHSS), particularly in high-responder patients.

Safety and Tolerability

HCG has a long clinical track record. Common adverse effects include injection site pain, headache, fatigue, and mood changes. In males, gynecomastia can occur due to increased aromatization of testosterone to estradiol. In females undergoing fertility treatment, OHSS represents the most significant risk, ranging from mild (abdominal bloating, nausea) to severe (ascites, pleural effusion, thromboembolic events).

Prolonged HCG use at high doses in males can lead to desensitization of Leydig cells, potentially reducing testosterone production capacity. This is an important consideration for long-term protocols and underscores the importance of appropriate dosing and clinical monitoring.

Regulatory Status

HCG has been FDA-approved for decades in both urinary-derived (Pregnyl, Novarel) and recombinant (Ovidrel) formulations. However, the regulatory landscape shifted significantly in March 2020 when the FDA reclassified HCG as a biologic under the Biologics Price Competition and Innovation Act (BPCIA). This reclassification meant that compounding pharmacies could no longer produce HCG under the traditional Section 503A/503B compounding pathway without a biologics license application (BLA).

This regulatory change significantly impacted access and cost for patients, particularly those using HCG as a TRT adjunct. Commercial formulations remain available but at higher cost, and some clinics have shifted to alternative approaches such as gonadorelin or enclomiphene to maintain endogenous testosterone production.